ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Two important problems for patients with HIV infections receiving highly active antiretroviral therapy (HAART) are its potential to elevate cholesterol and triglyceride levels, and the development of resistance to one or more agents in their treatment regimen. Studies presented at the 10th Conference on Retroviruses and Opportunistic Infections [Boston, US; February 2003] suggest that treatment with the investigational protease inhibitor (PI) atazanavir has advantages over established PIs with respect to these concerns. Results from an open-label study indicated that atazanavir has durable efficacy, with responses maintained after 108 weeks' treatment in patients receiving the drug in addition to lamivudine and stavudine. Furthermore, switching to atazanavir was shown to improve serum lipid profiles in patients previously treated with nelfinavir, while improving virological response rates. In an analysis of data from several studies, atazanavir was shown to have a unique resistance profile, with researchers suggesting that early use of, and development of resistance to, the drug does not affect − and may in fact enhance − susceptibility to other PIs in later treatment regimens.

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Rosacea is a chronic skin condition of unknown cause that is characterised by episodes of facial flushing, redness, lesions and pustules; it most commonly affects adults with fair skin. Although not life-threatening, the effect of rosacea on patients' appearance adversely affects their quality of life. Patients with rosacea are likely to require long-term treatment; convenient, well-tolerated topical therapies with minimal systemic effects are, therefore, desirable. A study presented at the 61st Annual Meeting of the American Academy of Dermatology [San Francisco, US; March 2003] has shown that a topical gel containing azelaic acid [AzA gel, `Finacea', `Skinoren'] is more effective than metronidazole, the current standard treatment for rosacea. The study demonstrated that treatment with azelaic acid 15% gel provided significantly greater mean reductions in inflammatory lesion counts and erythema severity, compared with metronidazole 0.75% gel. Furthermore, azelaic acid was shown to provide continuous improvements, whereas the effects of metronidazole reached a plateau after week 8. These results were confirmed by data from two vehicle-controlled phase III studies in which outcomes in azelaic acid recipients were similar to those from the comparative study ."The results showed that AzA gel is promising as a new therapy for patients with this type of moderate rosacea",said Dr Diane Thiboutot from Penn State College of Medicine, Hershey, US.

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS